title: Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.
abstract: BACKGROUND
  This study determine oxidative stress and survival prospectively in advanced stage non small cell lung cancer (NSCLC) patients following cisplatin based combination chemotherapy.
  
  
  METHODS
  The oxidative stress levels (LPO, NO, GSH and SOD) of 144 control subjects and 203 advanced stage (IIIA/IIIB/IV) newly diagnosed NSCLC patients were assessed at pre-treatment (day '0'), and after the 3rd and 6th cycles of chemotherapy. Groups were compared by repeated measures ANOVA while comparison of survival curves was conduced by Kaplan-Meier methods.
  
  
  RESULTS
  The pre-treatment mean levels of LPO and NO in patients were significantly (P<0.01) higher while GSH and SOD were significantly (P<0.01) lower as compared to control. The oxidative stress was elevated more significantly (P<0.01) after the chemotherapy and was more evident in higher stage than lower stage patients. The two year overall survival (%) of stage IV patients was significantly lower (P<0.05) as compared to stage III A and III B. The proportional mortality was also maximal in stage IV patients (37.0%) followed by stage III B (31.7%) and III A (20.0%).
  
  
  CONCLUSIONS
  Cisplatin based combination chemotherapy induces oxidative stress in NSCLC patients.
authors.affiliation: Department of Pathology, Era's Lucknow Medical College and Hospital, Sarfarazganj, Moosa bagh, Picnic spot, India. inansrivastava@gmail.com
authors.forename: Anand Narain
authors.initials: AN
authors.lastname: Srivastava
authors.forename: Abhilasha
authors.initials: A
authors.lastname: Gupta
authors.forename: Shruti
authors.initials: S
authors.lastname: Srivastava
authors.forename: S M
authors.initials: SM
authors.lastname: Natu
authors.forename: Balraj
authors.initials: B
authors.lastname: Mittal
authors.forename: M P S
authors.initials: MP
authors.lastname: Negi
authors.forename: Rajendra
authors.initials: R
authors.lastname: Prasad
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy* / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D013482:Superoxide Dismutase / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009569:Nitric Oxide; D005047:Etoposide; D013482:Superoxide Dismutase; D002945:Cisplatin